September 22, 2011
After winning US approval in May, the new hepatitis C virus treatment telaprevir has been OK'd by EU regulators, Vertex Pharmaceuticals and Johnson & Johnson said Tuesday. J&J has European rights to the drug; Vertex, which holds exclusive US rights, will receive European royalties. The action was anticipated, given that the European Medicines Agency recommended approval in July. Sold under the brand name Incivek in the United States, telaprevir will be branded as Incivo in Europe. In studies, telaprevir administered with standard HCV treatment nearly doubled the cure rate achieved by standard treatment alone.
09.20.2011; Anand Basu
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|'Caring at Its Essence': HIV Nurses Recall Pivotal Moments With Patients|
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|In Their Words: Burdens of HIV Nursing Include Lack of Respect and Resources|
|Conversations With Federal HIV Leaders From the 2017 U.S. Conference on AIDS|